Drilldown: Medicines

Famotidine (1) · Insulin aspart (1)

NovoLog, Fiasp (ultra-rapid), Trurapi (1) · Pepcid, Pepcid AC, Pepcid Complete (1)

[[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) · [[:Category:Insulins|Insulin]] (1) · [[:Category:Mealtime_insulins|Mealtime (bolus) insulin]] (1) · [[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]] (1)

None (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1)

'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1) · '"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"' (1)

20 mg PO twice daily, or 40 mg at bedtime (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1)

10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) · 100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1)

160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) · Titrated to glucose; no fixed maximum (1)

None · Oral · IV · Topical · IM · intranasal · rectal · Subcutaneous · topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · Sublingual · thigh · inhaled · SC · intra-articular

Other values:

Search

1 hour PO; minutes IV (1) · SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · ~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"' (1)

40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · ~100% from subcutaneous depot (1)

Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)